Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.43 |
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407667 | 0.89 | EGFR (0.42) | EGFRSRCKDR | |
| Trifluoroacetic Acid SCHEMBL6402916 | 0.87 | EGFR (0.41) | EGFRSRCKDRERBB2FGFR1 | |
| SCHEMBL6429537 | 0.83 | EGFR (0.47) | EGFRSRCKDRERBB2FGFR1 | |
| SCHEMBL4032843 | 0.82 | EGFR (0.61) | EGFRSRCKDRERBB2 | |
| SCHEMBL6405839 | 0.79 | EGFR (0.49) | EGFRSRCKDRERBB2 | |
| SCHEMBL6403835 | 0.79 | SRC (0.54) | EGFRSRCKDRERBB2FGFR1 | |
| SCHEMBL4033942 | 0.76 | EGFR (0.56) | EGFRSRCKDR | |
| SCHEMBL4033519 | 0.75 | EGFR (0.77) | EGFRSRCKDRERBB2 | |
| SCHEMBL4039322 | 0.75 | EGFR (0.56) | EGFRSRCKDRERBB2 | |
| SCHEMBL4034849 | 0.74 | EGFR (0.55) | EGFRSRCKDRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885SRC 111/4885KDR 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.